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The complement system is an ancient innate immune defense mechanism that can
recognize molecular patterns on the invading pathogens. Factor H, as an inhibitor of
the alternative pathway, down-regulates complement activation on the host cell surface.
Locally synthesized factor H at the site of infection/injury, including lungs, can act as a
pattern recognition molecule without involving complement activation. Here, we report
that factor H, a sialic acid binder, interacts with influenza A virus (IAV) and modulates IAV
entry, as evident from down-regulation of matrix protein 1 (M1) in H1N1 subtype-infected
cells and up-regulation of M1 expression in H3N2-infected A549 cells. Far-western
blot revealed that factor H binds hemagglutinin (HA, ∼70 kDa), neuraminidase (NA,
∼60 kDa), and M1 (∼25 kDa). IAV-induced transcriptional levels of IFN-α, TNF-α,
IL-12, IL-6, IFN-α, and RANTES were reduced following factor H treatment for the
H1N1 subtype at 6 h post-infection. However, for the H3N2 subtype, mRNA levels of
these pro-inflammatory cytokines were enhanced. A recombinant form of vaccinia virus
complement control protein (VCP), which like factor H, contains CCP modules and has
complement-regulatory activity, mirrored the results obtained with factor H. Both factor
H (25%), and VCP (45%) were found to reduce luciferase reporter activity in MDCK cells
transduced with H1N1 pseudotyped lentiviral particles. Factor H (50%) and VCP (30%)
enhanced the luciferase reporter activity for H3N2, suggesting an entry inhibitory role of
factor H and VCP against H1N1, but not H3N2. Thus, factor H canmodulate IAV infection
and inflammatory responses, independent of its complement-related functions.
Keywords: innate immunity, complement, factor H, vaccinia virus complement control protein, influenza A virus,
pseudotyped lentiviral particles, cytokine storm
INTRODUCTION
Influenza A virus (IAV) is a severe respiratory pathogens, belonging to the Orthomyxoviridae
family and responsible for outbreaks with high morbidity, and mortality in both humans
and animals (1). IAV exhibits antigenic variations within viral surface glycoproteins, including
hemagglutinin (HA), and neuraminidase (NA) (2). HA is the most important viral glycoprotein
that can bind to sialic acid on host cells, enabling cellular fusion and viral entry (3). HA
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epitopes are also known to trigger synthesis of neutralizing
antibodies by B cells, allowing IAV to escape from immune
surveillance, leading to seasonal epidemics (4). NA cleaves sialic
acid moieties, which enables release of virions, and promotes IAV
dispersion (5). There are around 16 antigenic variants of HA
and 9 of NA, which are found in numerous combinations and
subtypes (2, 6). Among all subtypes of IAV, H1N1 and H3N2
are the predominant IAV subtypes for seasonal flu in humans,
with annual epidemics estimated to result in ∼5 million cases of
severe illness and half a million respiratory deaths (7). Current
circulating human IAV strains are likely to continue acquiring
mutations resulting in antigenic drift and shift of HA and NA
glycoproteins (8, 9), which enhance the virus’ ability to evade host
immune system, promoting rapid viral invasion and replication.
Airway and alveolar epithelial cells are the primary targets
for IAV, which uses sialic acid as receptors, causing damage
to the alveolar epithelium (10, 11). Individuals infected with
IAV may become susceptible to acute respiratory distress
syndrome (ARDS) (12, 13). Lung epithelial cells express mucin
glycoproteins, such as MUC5AC, MUC5B, and MUC1, which
play an important role in restricting IAV infectivity (14–16).
These mucins are rich in sialic acid, serve as viral receptors,
and restrict viral binding to the target cells (16–18). However,
NA can attenuate the biological activity of these mucins (18,
19). The D151G mutation is a well-known mutation in NA
glycoprotein, which is responsible for its interaction with human
α2-6 and avian α2-3 linked sialic acid, mediating the H3N2 viral
association with sialic acid receptors. However, this mutation is
reported to reduce the enzymatic action of NA that is required
for HA detachment from its receptors (19, 20). Early defense
against invading IAV by the innate immune system is crucial
in limiting viral replication and invasion. The complement
system, a major humoral wing of innate immunity, offers a
crucial protective mechanism against IAV infection (21). This
includes neutralization, aggregation, opsonization and lysis of
viral particles, and induction of phagocytosis via complement
receptors (22, 23). A number of in vitro and in vivo studies have
established the protective role of the complement system against
IAV (24–27).
In the alternative pathway of the complement system, factor H
is an important negative regulator that interacts with negatively
charged surfaces containing sialic acids and glycosaminoglycans,
and protects cellular structures from C3 convertase formation,
hence diminishing complement activation. Factor H is a
soluble, 155 kDa glycoprotein present at a concentration of
128–654µg/ml in human plasma (28). It is composed of 20
complement control protein (CCP) modules with different
ligand binding properties. There is plenty of evidence of the
local extrahepatic synthesis of factor H [reviewed in (30)].
Factor H binds to many pathogens via charge interactions
(29), and for pathogens, surface-bound factor H may be of
benefit for their survival. Factor H binds to sialic acids on
Neisseria gonorrhoeae (30) and the outer surface of OspE of
Borrelia burgdorferi, providing complement resistance to these
pathogenic microbes. Its interaction with soluble West Nile
virus NS1 protein has also been described (31). Furthermore,
Plasmodium falciparum binds factor H and factor H-like protein
1 (FHL-1) to prevent complement-mediated lysis in themosquito
midgut via the plasmodial transmembrane gliding-associated
protein 50 (GAP50) (32). Factor H can also bind to the surface
of mycobacteria, restrict their uptake by macrophages, and
modulate pro-inflammatory cytokine responses (33).
Viruses employ diverse strategies to protect their viral
lipid envelopes from complement lysis by encoding or
recruiting complement inhibitors, with structural and functional
similarities to complement control proteins (CCP). Vaccinia
virus complement control protein (VCP) is a well-known
complement inhibitor, secreted by vaccinia virus infected
cells. VCP has inhibitory activity for both classical and
alternative pathways (34). Further examples of viral regulation of
complement includes binding of West Nile virus non-structural
protein (NS1) to factor H, or association of Nipah virions with
factor I, thus restricting complement activation (31, 35). In
addition, NS1 serves as a key inhibitor of innate immunity
as it blocks the synthesis and signaling of type 1 interferons
(IFNs) (36). NS1 also induces apoptosis in human airway
epithelial cells during IAV infection via caspase-dependent
mechanisms (37).
Since factor H can bind to sialic acids, a natural ligand for
IAV, it is of interest to examine potential influence of factor
H in competitively inhibiting IAV interaction with host cell
surfaces. This study was designed to investigate the complement
independent functions of factor H in the regulation of IAV
infection in vitro. Here, we report the ability of human factor H
and recombinant VCP to act as entry inhibitors of IAV.
MATERIALS AND METHODS
Viruses and Reagents
The IAV subtypes used in this study, including the pH1N1
(A/England/2009) and H3N2 (A/HK/1999), were provided
by Wendy Barclay (Imperial College, London) and Leo
Poon (University of Hong Kong), respectively. The plasmids
used for the production of H1N1 and H3N2 pseudo-typed
viral particles were obtained from Addgene; pHIV-Luciferase
(Addgene plasmid #21375); psPAX2 (Addgene plasmid #
12260); and Vesicular Stomatitis Virus (VSV-G) (Addgene
plasmid #8454). pcDNA3.1-swineH1-flag (H1 from swine
H1N1 A/California/04/09) (Invitrogen), pcDNA3.1-swine N1-
flag (N1 from swine H1N1 A/California/04/09), and pCDNA
H3 (from A/Denmark/70/03 (H3N2) (Invitrogen) were obtained
commercially. pI.18-N2 [N2 from A/Texas/50/2012/(H3N2)]
plasmid was a gift from Nigel Temperton (University of
Kent). Anti-influenza antibodies used were obtained from BEI
Resources, NIAID, NIH, USA, and used as previously described
(38); these include polyclonal anti-influenza Virus H3 HA,
A/Hong Kong/1/1968 and monoclonal anti-influenza virus H1
HA, A/California /04/2009.
Purification of Human Complement
Factor H
Complement factor H was purified from human plasma, as
described previously (39), using an affinity column made up of
a monoclonal antibody against human factor H (MRCOX23)
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coupled to CNBr-activated Sepharose (GE healthcare, UK).
Freshly thawed human plasma (Fisher Scientific) was adjusted
to 5mM EDTA, pH 8, and dialyzed overnight against Buffer
I (25mM Tris-HCL, 140mM NaCl, and 0.5mM EDTA, pH
7.5). MRCOX23 Sepharose column was washed with three bed
volumes of buffer I, and dialyzed plasma was passed through
the column. The column was then washed again with the same
buffer and factor H was eluted using 3M MgCl2, pH 6.8. The
eluted fractions were dialyzed against H2O overnight, followed
by 10mM potassium phosphate pH 7.4. The samples were then
analyzed for purity by 12% v/v SDS-PAGE.
Purification of Recombinant Vaccinia Virus
Complement Control Protein Expressed in
HEK293 Cell Line
The VCP gene (accession X13166.1) was codon-optimized
for expression in human embryonic kidney (HEK) cells
by GeneArt R© using GeneOptimizer R© (Geneart GmbH,
Regensburg). For lentiviral expression, amplified VCP cDNA
was ligated into the pLenti6/V5-D-TOPO vector, using the
ViraPower Lentiviral Directional TOPO Expression kit,
according to the manufacturer’s instructions (K4950-00
Invitrogen Corp, Carlsbad CA). Following transformation into
DH5α chemically competent E. coli cells, a number of colonies
were analyzed for correct insertion and orientation using colony
PCR. Transient transfection of the plasmid pLenti6/V5/VCP
in HeLa cells and indirect immunofluorescence using anti-V5
antibody (Invitrogen # R960-25) was performed to verify the
VCP expression. Replication-incompetent lentiviral stock was
made by co-transfection with the ViraPowerTM Packaging Mix
(pLP1, pLP2, and pLP/VSVG: K4975-00, Invitrogen Corp) in
HEK 293FT cells (ATCC CRL-1573) cells using Lipofectamine
2000 R© reagent (Life Technologies Inc.), according to the
manufacturer’s instructions. Forty-eight hours after co-
transfection, viral supernatant was collected, concentrated by
centrifugation, and the titer was determined using standard
procedures. A number of stable HEK 293FT cell lines expressing
VCP were generated under neomycin selection (0.5 g/L) and
screened for VCP expression by Western blot analysis. Three
clones of HEK-293 cells secreting high levels of the VCP were
selected and cultured. Secreted VCP was purified using a heparin
column. Column-bound proteins were eluted with a linear salt
gradient (0–0.5M NaCl). Fractions were collected and analyzed
via SDS-PAGE and western blotting.
Cell Culture and Treatments
Madin Darby Canine Kidney (MDCK) and Adenocarcinomic
human alveolar basal epithelial cells (A549) cells (ATCC,
Rockville, MD, USA) were cultured in complete DMEM media,
supplemented with 10% v/v fetal calf serum, 2mM L-glutamine,
and penicillin (100 U/ml)/streptomycin (100µg/ml) (Thermo
Fisher), at 37◦C under 5% v/v CO2, with fresh complete medium
added every 2–3 days until 80% confluence was reached. Cell lines
used in this study were subjected to a maximum of 7 passages for
in vitro experiments.
Production of IAV Subtypes and
Pseudotyped Viral Particles, and TCID50
(Median Tissue Culture Infectious Dose)
Assay
50,000 MDCK cells at 80% confluency were infected either
with pH1N1 (2 × 104) or H3N2 (3.3 × 104) particles
and incubated in complete DMEM medium at 37◦C for
1 h. Unbound viral particles were removed and replaced
with infection medium, composed of DMEM with 0.3%
bovine serum albumin (BSA), 1% penicillin/streptomycin, and
1µg/ml of l-1-tosylamido-2-phenylethyl chloromethyl ketone
(TPCK)— Trypsin (Sigma –Aldrich), and incubated for 3 days
under culture conditions, as mentioned above. Post infection,
supernatant was subjected to ultra-centrifugation (25,000 ×
g) for 90min at 4◦C. Purified viral particles were then re-
suspended in PBS, and purity of the virus was analyzed by
SDS-PAGE and western blotting. Production of pseudotyped
particles was carried out, as described earlier (38). Briefly,
HEK293T cells were co-transfected with 20µg of respective IAV
pCDNAs, including pcDNA3.1-swineH1-flag (H1 from swine
H1N1 A/California/04/09) (Invitrogen), pcDNA3.1-swine N1-
flag (N1 from swine H1N1 A/California/04/09) (Invitrogen),
pcDNA-H3 [H3 from A/Denmark/70/03/(H3N2)], pI.18-N2
[N2 from A/Texas/50/2012/(H3N2)], pHIV-Luciferase backbone
(Addgene), and psPAX2 (Addgene). VSV-G was generated
similarly, without H1N1 and H3N2 pcDNAs. The released
H1N1, H3N2, and VSV-G pseudotyped lentiviral particles were
harvested in the supernatant at 48 h. Harvested supernatant was
centrifuged at 5,000 × g for 20min, and the clear supernatant
without any debris was concentrated using ultra centrifugation
(25,000× g) for 90min. The ultra-centrifuged lentiviral particles
were re-suspended in sterile PBS and analyzed via TCID50,
western blotting and luciferase activity assay. TCID50 assay
was carried out to determine the viral titer and cytopathic
effects of infected cells (40). Briefly, MDCK cells (1 × 105)
were infected with either purified pH1N1 and H3N2 viral
parties or pseudotyped lentiviral particles, incubated at 37◦C
for 3 days under 5% v/v CO2, until a cytopathic effect was
observed in terms of structural changes in MDCK cells caused
by viral invasion.
Hemagglutination Inhibition Assay
In a 96 microtiter well plate, 25 µl of PBS was added to each well.
In the first column, a starting concentration (total volume 50 µl)
of 20 µg of factor H was serially diluted (25 µl) to achieve final
quantities of 20, 10, 5, and 2.5 µg of factor H per well. Twenty-
five microliters of respective IAV subtype particles were added to
wells, except for PBS control wells, at the dilutions corresponding
to their respective HA titer to initiate hemagglutination. Plates
were gently mixed and incubated at 37◦C for 1 h. Fifty microliter
of 0.75% v/v guinea pig RBCs was added to each well; plates
were gently mixed and incubated at room temperature for 1 h.
Inhibition of hemagglutination appeared as a halo or circle of
settled cells in the center of round-bottomed wells. Absence
of inhibition was observed as a uniform red color across the
well (hemagglutination).
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ELISA to Detect Interaction of Factor H
and VCP With IAV Subtypes
Factor H or VCP (5, 2.5, 1.25, and 0.625 µg/well in 100
µl volume) were coated onto 96-well microtiter plates using
carbonate-bicarbonate buffer (CBC), pH 9.6, and incubated at
4◦C overnight. After washing the microtiter wells with PBS, the
wells were blocked with 2% w/v BSA in PBS and incubated
at 37◦C for 2 h, followed by three PBST (PBS + 0.05% v/v
Tween 20) washes. Twenty microliters of H1N1 or H3N2 virus
(1.36 × 106 pfu/ml) in PBS were added to each well and
incubated at 37◦C for 2 h in the presence of 5mM CaCl2.
VSV-G pseudotyped lentivirus was used as a negative control.
Following PBST washes, the corresponding wells were incubated
with primary antibodies (100 µl/well): polyclonal anti-influenza
virus H3 and monoclonal anti-influenza virus H1 (1:5,000) (BEI-
Resources). The wells were again washed with PBST three times
and probed with Protein A-HRP-conjugate, or goat anti-mouse
IgG-horseradish peroxidase (HRP)-conjugate (1:5,000) (Fisher
Scientific), followed by incubation at 37◦C for 1 h. Color was
developed using 3,3′, 5,5′-tetramethylbenzidine (TMB) substrate
(Sigma-Aldrich), and reaction was stopped using 1M H2SO4,
followed by measuring absorbance at 450 nm, using iMarkTM
microplate absorbance reader (Bio-Rad).
Cell Binding Assay to Detect IAV
Interference With Factor H and VCP
A549 cells (1 × 105 cells/well) were seeded in 96 microtiter
wells and incubated at 37◦C overnight in 5% v/v CO2. Once
80% confluency was reached, the cells were washed twice with
sterile PBS. Factor H or VCP (10, 5, 2.5, 1.25µg/ml), pre-
incubated with H1N1 and H3N2 (1.36 × 106 pfu/ml) IAV
subtypes, were added to the wells (in 5mMCaCl2) and incubated
at room temperature for 2 h. BSA was used as a negative control.
Following washes with PBS three times, the corresponding wells
were fixed with 4% v/v paraformaldehyde (Fisher Scientific) for
5min at room temperature. The wells were then blocked with 2%
w/v BSA for 2 h at 37◦C. Polyclonal anti-influenza virus H3 (BEI-
Resources) and monoclonal anti-influenza H1 (BEI-Resources)
were added to the appropriate wells and incubated at 37◦C
for 1 h. After gentle washes with PBSST, the wells were probed
with protein A-HRP conjugate or goat anti-mouse IgG-HRP-
conjugate (Thermo-Fisher) diluted in PBS in 1:5,000 dilution and
incubated at 37◦C for 1 h. The wells were washed again with
PBST; the color was developed by adding TMB substrate and the
reaction was stopped by using 1M H2SO4. The absorbance was
read at 450 nm using an ELISA plate reader.
Far-Western Blotting
Purified H1N1/H3N2 (1.36 × 106 pfu/ml) virus particles were
run on a 12% (w/v) SDS-PAGE, and transferred onto a PVDF
membrane for 2 h at 320mA in transfer buffer (25mM Tris–
HCl, pH 7.5, 20% v/vmethanol, and 190mMglycine).Membrane
was blocked with PBS+5% w/v BSA (Sigma-Aldrich) at room
temperature, followed by PBST washes. The membrane was then
incubated with 10µg/ml of factor H or VCP overnight at 4◦C,
and probed appropriately with either monoclonal mouse anti-
human factor H (MRCOX23) (MRC Immunochemistry Unit,
Oxford) (1 mg/ml) or rabbit anti-VCP polyclonal antibody (0.5
mg/ml) (King Faisal Specialist Hospital and Research Center,
Saudi Arabia) at room temperature for 1 h. Following PBST
washes (three times, 10min each), the membrane was incubated
with secondary antibody, rabbit anti-mouse IgG HRP conjugate
(1:1,000) (Sigma-Aldrich) or Protein A-HRP-conjugate for 1 h
at room temperature. The secondary antibody was removed,
followed by PBST washes; then the membrane was developed
using 3,3′-diaminobenzidine (DAB).
Infection Assay for Extracting RNA
A549 (5 × 105/well) cells were cultured in complete DMEM
and grown overnight at 37◦C in a CO2 incubator. Once 85%
cell confluency was reached, the cells were washed gently with
fresh PBS and replaced with DMEMwithout FBS. Forty µg/ml of
factor H or VCP was added to corresponding wells, with a MOI
= 1:1 of pH1N1, and H3N2 or pseudotyped viral particles (333
µl/ml) at room temperature for 1 h and at 4◦C for another hour.
The unbound virus and protein were removed by pipetting out
the supernatant. The cells were washed gently again with PBS,
and placed in 1ml of infection medium to initiate viral infection
of the host cells being incubated for 2 and 6 h. After removing
the supernatant, the infected cells were washed with PBS and
detached using 2 × Trypsin-EDTA (0.5%) (Fisher Scientific),
centrifuged at 1,500 x g for 5min, and the cell pellet was frozen at
−80◦C for RNA extraction.
Quantitative RT-PCR Analysis
The virus infected cell pellets were lysed using lysis buffer (50mM
Tris–HCl, pH 7.5, 200mM NaCl, 5mM EDTA pH 8, 0.1% v/v
Triton X-100). GenElute Mammalian Total RNA Purification Kit
(Sigma-Aldrich) was used to extract the total RNA, as per the
manufacturer’s instructions. Once RNA was extracted, DNase I
(Sigma-Aldrich) treatment was performed to remove any DNA
contaminants, followed by quantifying the amount of RNA
at A260 nm using a NanoDrop 2000/2000c (Fisher-Scientific).
The purity of RNA was assessed using the ratio A260/A280.
Two micrograms of total RNA was used to synthesize cDNA,
using High Capacity RNA to cDNA Kit (Applied Biosystems)
and cDNA conversion was performed. The primer BLAST
software (Basic Local Alignment Search Tool) was used to design
primer sequences as listed in Table 1. The qRT-PCR assay was
performed using the StepOne Plus system (Applied Biosciences).
Each qPCR reaction was conducted in triplicates, containing
75 nM of forward and reverse primers, 5 µl Power SYBR
Green MasterMix (Applied Biosystems), and 500 ng of cDNA.
qPCR samples were run for 50◦C and 95◦C for 2 and 10min,
followed by running the amplification template for 40 cycles,
each cycle involving 15 s at 95◦C and 1min at 60◦C. Eighteen
seconds RNA was used as an endogenous control to normalize
the gene expression.
Statistical Analysis
The graphs were generated using the GraphPad Prism 6.0
software, A one-way ANOVA test was carried out for statistical
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significance. Significant values were considered based on ∗p <
0.05, ∗∗p< 0.01, and ∗∗∗p< 0.001, between treated and untreated
conditions. Error bars show the SD or SEM, as indicated in the
figure legends.
RESULTS
Factor H Inhibits Hemagglutination of
Guinea Pig Red Blood Cells by IAV
Factor H was purified from human plasma, using monoclonal
MRCOX23 Sepharose affinity column (39). The purity of the
eluted protein was confirmed by SDS-PAGE; the molecular
weight of factor H was evident at ∼155 kDa (Figure 1A).
Recombinant VCP appeared pure and migrated at ∼35 kDa
(Figure 1B). Guinea pig RBCs were used to determine if addition
TABLE 1 | Primers used for target genes in qPCR.

























IFN-α 5′-TTT CTC CTG CCT GAA GGA
CAG-3′
5′-GCT CAT GAT TTC TGC TCT
GAC A-3′
of factor H would inhibit hemagglutination by IAV subtypes
(Figure 2). Five IAV strains of H3N2 or H1N1 subtypes were
tested. The basic principle of this assay relies on the specific
feature of envelope viral glycoproteins that can interact with
sialic acid on RBCs. In the absence of viral particles, RBCs
sedimented under gravity, forming a distinct red halo at the
bottom of the microtiter well (Figure 2). However, in the
presence of viral particles, glycoproteins of virus (HA or NA in
this case) interact and bind with sialic acid on RBCs, forming
clumps, leading to a lattice formation, where RBCs remain in
suspension. Factor H partially inhibited the hemagglutination
of IAV strains. Low concentration of factor H (2.5µg/ml)
was more potent in inhibiting hemagglutination of H1N1 than
H3N2 strains. Hemagglutination of all strains was effective using
10µg/ml of factor H. It is possible that factor H binds to
the IAV particles, restricting the binding of virus to RBCs,
allowing them to form a halo at the bottom of the wells. PBS
alone, in the absence of IAV particles, led to the formation
of a halo at the bottom of the microtiter well, suggesting
no hemagglutination.
Factor H and VCP Bind IAV Envelope
Glycoproteins
Since factor H was able to inhibit hemagglutination by H1N1
and H3N2 IAV subtypes, a direct ELISA was set up with factor
H -coated plates to establish possible interaction with IAV
viruses (Figure 3). We also examined, for the first time, the
likely interaction between IAV and VCP, which contains CCP
modules (4) like human factor H. A/England/2009 (H1N1) and
A/Hong Kong/1999 (H3N2) strains were used in this study. A
comparable dose-dependent binding by factor H and VCP was
evident with H1N1 (Figure 3A) and H3N2 (Figure 3B) subtypes.
VSV-G pseudotyped lentivirus was used as a negative control,
FIGURE 1 | 12% (w/v) SDS-PAGE analysis of complement factor H purified from human plasma (A), and a recombinant form of vaccinia virus complement control
protein (VCP) expressed in HEK 293FT cells (B). The purified protein was run under reducing conditions: Factor H appears as ∼155 kDa band, and VCP was
observed at ∼35 kDa.
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FIGURE 2 | Hemagglutination assay. Inhibition of hemagglutination by purified
human factor H was tested on human IAV subtypes. Guinea pig red blood
cells were incubated with either PBS or IAV subtypes with and without various
concentrations of factor H (20, 10, 5, and 2.5 µg).
which did not show any binding with either factor H or VCP.
The ability of factor H and VCP to interfere with IAV binding to
A549 cells was then assessed via the cell binding assay (Figure 4).
An increase of IAV binding in presence of factor H and VCP was
seen at the concentration of 10µg/ml for both H1N1 and H3N2
IAV subtypes, and the binding occurred in a dose and calcium
dependent manner (Figure 4), suggesting that factor H and VCP
enhance binding of IAV to target cells, which in turn interferes
with viral infection in a complement-independent manner. The
binding of factor H and VCP was more effective in the case
of H1N1 than H3N2. We then set up a far western blot to
identify viral particles binding to factor H and VCP (Figure 5).
In this assay, virus subtypes (H1N1 and H3N2) separated on
SDS-PAGE were transferred to a nitrocellulose membrane and
were probed with either 10µg/ml factor H or VCP. The far
western blot also revealed the binding of factor H and VCP to
HA (∼70 kDa), and M1 (∼25 kDa) of both H1N1 and H3N2
IAV subtypes (Figure 5). Furthermore, factor H also bound to
FIGURE 3 | Binding between factor H or VCP with H1N1 (A), and H3N2 (B)
IAV subtypes were determined via ELISA. Microtiter wells were coated with
various concentrations of factor H, VCP or VSV-G (0.625, 1.25, 2.5, and 5
µg/well) in carbonate bicarbonate buffer, pH 9.6 overnight at 4◦C. H1N1 or
H3N2 virus (1.36 × 106 pfu/ml) was added to each well in the presence of
5mM CaCl2 and probed with either monoclonal anti-influenza virus H1 or
polyclonal anti-influenza virus H3 antibody. VSV-G pseudotyped particles were
used as a negative RNA virus control. The data were expressed as mean of
three independent experiments done in triplicates ± SEM.
NA (∼55 kDa) of H3N2 strain more strongly compared to
H1N1 strain.
Modulation of IAV Infectivity by Factor H
and VCP in A549 Cells
In view of factor H and VCP binding to key IAV proteins, an
infection assay was set up to assess the impact of this interaction
on viral infectivity and replication by factor H and VCP.
A549 lung epithelial cells, infected with H1N1 and H3N2 with
and without factor H or VCP (40µg/ml), showed differential
expression of M1 mRNA levels at 2 and 6 h post-infection
(Figure 6). In the case of H1N1, both factor H and VCP led to
the down-regulation (−4 log10) of viral M1 transcription at 6 h.
However, an up-regulation was seen with H3N2 (2log10) subtype
following factor H and VCP treatment, suggesting that the
inhibitory effect by these proteins is strain specific (Figure 6A).
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FIGURE 4 | Cell-binding assay to show binding of factor H (A) and VCP (B) to A549 cells challenged with H1N1 and H3N2. A549 cells (1 × 105 cells/ml) were
seeded in a 96-well microtiter plate and incubated at 37◦C overnight. Decreasing concentrations of factor H and VCP (10, 5, 2.5, and 1.25 µg), pre-incubated with
IAV subtypes, were added to the corresponding wells, and incubated at room temperature for 1 h. After removing unbound protein and viral particles, the wells were
fixed with 4% v/v paraformaldehyde, and probed with monoclonal anti-influenza virus H1 or polyclonal anti-influenza virus H3 antibodies. BSA was used as a negative
control protein. Three independent experiments were carried out in triplicates and error bars expressed as ± SEM.
Factor H and VCP Trigger an
Anti-inflammatory Response in the Case of
H1N1
qPCR data revealed that factor H and VCP treatment resulted
in the modulation of both pro and anti-inflammatory responses
(Figures 6B,C). Following factor H treatment of IAV-challenged
A549 cells, the mRNA levels of TNF-α were down-regulated
at 2 h (−5log10) and 6 h (−8log10) in H1N1 infected cells
(Figure 6B). However, an opposite effect was seen with H3N2
infected cells; the expression level of TNF-α was up-regulated,
although not dramatically, at 2 h (3log10), as well as at 6 h
(3.5log10) (Figure 6B). In H1N1 challenged cells, the mRNA
levels of IL-6 (−3.5log10) and RANTES (−0.5log10) were also
down-regulated at 2 h time point in the presence of factor
H. Conversely, IL-6 (2.5log10) and RANTES (1.5log10) levels
were up-regulated in H3N2 challenged cells at 2 and 6 h (IL-
6/3log10) (RANTES/2.5log10) treatment with factor H. Factor H
also down-regulated IL-12 levels in H1N1 (1log10) subtype at
6 h, but enhanced in H3N2 challenged cells at both 2 and 6 h.
We also show here, for the first time, the effect of VCP, which
contains 4 CCP modules like human factor H, on IAV infection;
it mirrored the results obtained with factor H (Figure 6B). A
greater down-regulation of TNF-α (−5log10), IL-6 (−3.5log10)
and IL-12 (−1.5log10) levels were seen at 6 h following VCP
treatment when compared to untreated control (cells + H1N1)
(Figure 6B). VCP treated H1N1 challenged A549 cells showed a
reduced level of RANTES at 2 h (−0.7log10), which was raised
slightly at 6 h. In the case of H3N2, effects similar to factor H
were observed (Figure 6B). TNF-α, IL-6, IL-12, and RANTES
were increased at 6 h VCP treatment. Higher levels of pro-
inflammatory cytokines, including TNF-α, IL-6, and IFN-α have
been detected in IAV infected patients (41), and correlate with
severe infectivity. H1N1 infected patients have higher levels of IL-
6 in their lungs and serum (42, 43). Therefore, down-regulation
of IL-6 by both factor H and VCP in H1N1 infected A549
cells suggests a possible anti-inflammatory role of these two
proteins in a strain specific manner. In addition, the ability of
factor H (−2log10) and VCP (−2.5log10) to down-regulate type
1 IFN-α (Figure 6C) at 6 h was also seen in H1N1. However,
higher expression levels of IFN-α were detected in the case of
H3N2 in the presence of factor H (2 log10) and VCP (1.7 log10)
(Figure 6C).
Factor H and VCP Act as Entry Inhibitors of
H1N1 Viral Infection
In this study, lentiviral pseudotypes were generated to determine
cell entry strategies of H1N1 and H3N2 subtypes of IAV.
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FIGURE 5 | Far western blot analysis to show factor H (A) and VCP (B) binding with purified H1N1 and H3N2. IAV subtypes (1.36 × 106pfu/ ml) were first run on the
SDS-PAGE under reducing conditions and transferred onto a nitrocellulose membrane. The transferred membrane was then incubated with 10µg/ml of factor H or
VCP. The membrane was probed with either monoclonal mouse anti-human factor H or polyclonal rabbit anti-VCP antibody. Factor H and VCP bound to HA (∼70
kDa), NA (∼55 kDa), and M1 (∼25 kDa) in the case of both IAV subtypes. The identities of factor H and VCP bound IAV glycoproteins were validated using a separate
blot that was directly probed with monoclonal anti-HA (C), anti-NA (D), and anti-M1 (E) antibodies.
Production of lentiviral pseudotypes was carried out by co-
transfecting HEK293T cells with plasmid containing the coding
sequence of IAV glycoprotein combinations such as H1+N1
and H3+N2, pHIV-Luciferase backbone, and psPAX2 plasmids
via a calcium phosphate transfection method. Post transfection,
H1N1 and H3N2 pseudotyped particles were harvested at
48 h, purified, and analyzed via western blotting. The HA
expression level was detected using anti-H1 polyclonal antibody;
HA was evident around ∼70 kDa (Figure 7A). MDCK cells
were transduced with purified H1N1 and H3N2 pseudotyped
particles to measure the luciferase reporter activity, with and
without factor H or VCP (40µg/ml). Nearly 25% reduction
in the luciferase reporter activity was observed for factor H
compared to cells only, challenged with H1N1 pseudotyped
particles (Figure 7B). However, factor H enhanced the luciferase
activity by 50% in cells transduced with H3N2 pseudotyped
particles. In the case of VCP,∼45% reduction of luciferase activity
for cells transduced with H1N1-pseudotyped particles was noted,
whereas it caused ∼30% increase of luciferase activity in cells
transduced with H3N2 pseudotyped particles (Figure 7B). Thus,
factor H and VCP seem to act as entry inhibitors only in the
case of H1N1.
DISCUSSION
Pathogens have evolved a range of defense mechanisms to
overcome the immune response modifying their infectivity and
dissemination in the host (44, 45). The complement system, a
major arm of the innate immune system, consists of several
soluble factors and cell surface receptors that interact with and
react to invading pathogens. Some pathogens mimic and recruit
complement inhibitors, such as factor H and C4b binding protein
(C4BP) to escape complement (46–48).
Factor H is an abundant plasma protein, which has a
regulatory function in the homeostasis of the complement system
and in the protection of bystander host cells and tissues from
injury via the complement activation of the alternative pathway
(31). The most important point in the complement activation
is the regulation of C3 convertase, which is monitored by
factor H, a well-established sialic acid binder. A number of
bacteria can recruit factor H via the presentation of specific
binding proteins, including factor H binding proteins (fHbp)
of Neisseria meningitidis (49), CspA and outer surface protein
E of Borrelia burgdorferi (50, 51), staphylococcal binder of IgG
from Staphylococcus aureus (52), and pneumococcal surface
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FIGURE 6 | Replication of IAV subtypes and inflammatory responses of A549 cells. (A) Following entry inhibition, replication of IAV subtypes (H1N1 and H3N2) is
affected by factor H and VCP in human A549 cells. M1 expression was monitored in A549 cells challenged with either H1N1 or H3N2 IAV subtypes (MOI 1) at
6 h. A549 cells were challenged with H1N1 and H3N2 pre-incubated with or without factor H and VCP (40µg/ml). Cell pellets were harvested at 6 h post-infection.
(Continued)
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FIGURE 6 | 18S rRNA was used as an endogenous control. Significance was determined using the unpaired one-way ANOVA test (**p < 0.01, and ***p < 0.001) (n
= 3). (B) Transcription expression profile of cytokines and chemokines produced by A549 in response to H1N1 and H3N2 challenge with and without factor H. 18S
rRNA expression was used as an endogenous control. Cells only was used as a calibrator sample to calculate relative quantitation (RQ); RQ = 2−11Ct. Experiments
were conducted in triplicates, and error bars represents ± SEM. Unpaired one-way ANOVA test was used calculate the significance (*p < 0.05, **p < 0.01, and ***p <
0.001) (n = 3). (UT, untreated sample; T, treated sample). (C) Expression levels of type I interferon alpha (IFN-α) following 6 h treatments with factor H and VCP. 18S
rRNA was used as an endogenous control. RQ = 2−11Ct was used to calculate the RQ value. Significance was determined using the unpaired one-way ANOVA test
(**p < 0.01) (n = 3).
FIGURE 7 | Factor H and VCP inhibit transduction of MDCK cells by H1N1-pseudotyped lentiviral particles. Western blotting to show expression of hemagglutinin
(HA) in purified H1N1 and H3N2 pseudotyped lentiviral particles (A). HA expression was evident at ∼70 kDa. Luciferase reporter activity of H1N1 and H3N2
pseudotyped lentiviral particles-transduced cells with factor H and VCP (B). Significance was determined using the unpaired one-way ANOVA test (**p < 0.01 and
***p < 0.001) (n = 3).
protein C of Streptococcus pneumoniae (53). The factor H ligands,
expressed by pathogens, are structurally distinct from each other,
but they share the related binding site on factor H that can
be localized on a common site of the CCP20 module (45).
These interactions increase the binding ability of CCP 19-20
modules to C3b, resulting in a stable complex between factor H,
C3b and microbial targets, with an enhanced co-factor activity.
Pseudomonas aeruginosa express sialic acid on their surfaces,
which reduces complement deposition via probable factor H
recruitment. Sialic acid also recruits siglec-7/9 leading to immune
escape (54). In addition, factor H binds to ApoE on High Density
Lipoprotein (HDL) via CCP 5-7 modules, and is used by the
bacteria to mimic the plasma HDL to increase their survival in
the blood (35).
Here, we investigated the complement-independent function
of factor H in the regulation of IAV infection. Since VCP is
an efficient complement inhibitor and a homolog of factor H
(34), we included it in the present study. VCP is a ∼35 kDa
secretory protein of vaccinia virus, encoded by the C3L open
reading frame (ORF), and contains four CCP modules (34). VCP
has been shown to inhibit complement lysis of sheep RBCs, by
binding to C3b and C4b (34), and serves as a cofactor in the
factor I-mediated cleavage of C3b and C4b (34). Additionally,
VCP has been shown to inhibit formation of C3 convertase
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and accelerate the decay of the alternative pathway (55). In the
present study, a direct and complement independent interaction
of factor H and VCP with H1N1 and H3N2 IAV subtypes
were examined via hemagglutination assay, ELISA, cell binding,
and far western blotting. In the hemagglutination assay, factor
H inhibited hemagglutination of both H1N1 and H3N2 IAV
subtypes; 10µg/ml being the most effective with H1N1 and
H3N2 subtypes.
VCP 4 modules contain a heparin binding site, as does factor
H (56). It is possible that in a manner similar to factor H
(57, 58), the heparin binding site found within the VCP protein
enhances its decay-accelerating action against C3 convertase.
SRBCs have high surface sialic acid. Factor H binds to this
and protects them from the complement alternative pathway.
On removal of the sialic acid with neuraminidase, SRBCs
become susceptible to complement lysis. However, other studies
suggest that the decay activity rate of VCP does not reduce
following neuraminidase-treatment of SRBCs (57, 58), indicating
a difference in reaction with sialic acids. Furthermore, a weaker
decay rate was seen with CCP 2–4 mutants of VCP. Factor
H and VCP seem to bind H1N1 and H3N2 via HA (∼70
kDa) and NA (∼55 kDa) in addition to recognizing M1. It is
well-known that the viral HA can bind to sialic acid residues
on surface glycoprotein and its receptor binding depends on
the nature of the glycosidic linkage (59). The binding of HA
to sialic acids, like factor H, is the initial event in the virus
association with human epithelial cells. In addition, the resulting
disruption of the neuraminic acid residues can enable the virus
to cross over the epithelial cells, thus entering new cells to initiate
viral replication.
The immune response of A549 cells following IAV challenge
in the presence and absence of factor H or VCP was examined
using qRT-PCR. The ability of factor H and VCP to modulate
viral replication, due to entry inhibition, was determined using
M1 mRNA expression levels between protein treated and un-
treated A549 cells challenged with H1N1 or H3N2 subtypes. Both
factor H and VCP modulated the IAV replication in a strain
dependent manner. In the case of H1N1, both factor H and VCP
showed reduced viral M1 expression; however, an increased M1
expression was seen for H3N2, suggesting that the inhibitory
effect of these proteins is strain-dependent. This suggests that
both factor H andVCP could act as entry inhibitors against H1N1
subtype, but not H3N2.
Several studies have demonstrated both direct and indirect
correlation between cytokine levels and viral replication (60,
61). IAV targets lung epithelial cells, and following initial
exposure, progeny viral particles proliferate to infect other
cells, including alveolar macrophages (62). Thus, an acute
inflammatory response is triggered by the activation of pro-
inflammatory cytokines and chemokines (62, 63), where higher
levels lead to a dramatic cytokine storm; altered levels of TNFs,
IFNs, interleukins and chemokines have been detected in IAV
infected patients (41). Over-synthesis of IFN levels during early
stages of IAV infection causes irreversible lung damage in
mice infected with H5N1; however, IFN signaling may also be
crucial in preventing H5N1 dissemination (64, 65). TNFs are
key soluble factors in the cytokine storm; H5N1 infected mice
deficient in TNF receptors, as well as H5N1 infected mice treated
with anti-TNF-α antibodies, show no change in survival rate
compared to healthy controls (66). Furthermore, IL-6 and IL-
1 are the crucial pro-inflammatory cytokines produced by the
host during influenza infection. Expression of IL-1 is detected
in the early stage of IAV infection, followed by an increased IL-
6 expression (67). H5N1 infected mice lacking in IL-6 receptor
have demonstrated a poor survival outcome, suggesting the
protective role of IL-6 pathway in the cytokine storm (67).
Therefore, an unbalanced cytokine storm can also lead to damage
in the vascular barrier, causing tissue oedema, capillary leakage,
failure of multiple organs, and death (67). However, no specific
singular mechanism is reported when it comes to triggering a
cytokine storm with respect to influenza strains.
In this study, alterations of cytokine levels were observed in
H1N1 and H3N2 challenged A549 cells in the presence of factor
H and VCP. Factor H treatment resulted in down-regulation of
TNF-α at 2 and 6 h in H1N1 infected cells. In the case of H3N2
infected cells, expression of TNF-α was up-regulated at 2 and 6 h
after treatment. ReducedmRNA levels of IL-6 and RANTES were
also seen at 2 h treatment with factor H, which slightly increased
at 6 h. Conversely, enhanced levels of IL-6 and RANTES were
observed in H3N2 infected cells following 2 and 6 h treatment
with factor H.
In the case of VCP, TNF-α IL-6, and IL-12 levels were
found to be down-regulated at 6 h treatment. H1N1 infected
cells treated with VCP also showed reduced levels of RANTES
at 2 h. H3N2 infected A549 cells following VCP treatment
revealed similar effects as factor H. Up-regulation of TNF-
α, IL-6, IL-12, and RANTES were observed at 6 h following
VCP treatment. Previous studies have reported enhanced serum
levels of pro-inflammatory cytokines, including TNF-α, IL-6, and
IFN-α in individuals infected with IAV (68). IL-6 and TNF-
α may be the key contributors to virus mediated respiratory
diseases, including Acute Respiratory Distress syndrome (ARDS)
and acute lung injury (69). During IAV infection, alveolar
macrophages are activated, which are the primary phagocytic
cells that produce robust amounts of IL-6 and TNF-α (70).
Macrophages infected with IAV have also been shown to produce
chemokines such as RANTES and monocytes chemotactic
protein-1 (MCP-1). This further recruits mononuclear cells to
the lungs and facilitates viral clearance (71), and enhances
production of those cytokines (e.g., TNF-α, IL-6, RANTES, and
IL-8) that are also implicated in the pathogenesis of influenza
virus. RANTES, IL-1β, IL-6, and TNF-α induced by influenza
result in pro-inflammatory Th1-type immune responses in the
infected host (71). Dysregulation of cytokine and chemokine
levels during influenza has been demonstrated to promote tissue
injury and impaired viral clearance. Additionally, suppression
of IFN-α was also evident with factor H and VCP in H1N1
challenged A549 cells. In the case of H3N2, both factor H and
VCP increased the expression of IFN-α, which may possibly
induce protection of A549 cells against H3N2 viral particles in
neighboring as well as non-infected cells. Thus, increased IFN-
α by factor H and VCP may also suggest that in the infected
A549 cells, factor H and VCP may cause digestion of viral RNA
and viral proteins. Down-regulation of IFN-α levels in H1N1
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infected cells may suggest the possibility of factor H and VCP
treatment to reduce the rate of viral replication. Thus, treatments
with factor H and VCP may elicit an anti-viral response,
restricting the activation of innate immune cells and associated
lung pathology.
Targeting viral entry into a host cell is an emerging approach
for developing anti-viral therapy as viral propagation can be
either restricted or blocked at an early stage of viral cycle,
minimizing drug resistance by released virions. In this study, we
have generated lentiviral pseudotypes, a safe surrogate model to
mimic the structure and surfaces of IAV in order to determine if
factor H and VCP act as an entry inhibitors in cells transduced
with pseudotyped IAV particles that are restricted to only one
replicative cycle. Factor H treatment resulted in 25% reduction
of luciferase reporter activity in MDCK cells transduced with
H1N1 pseudotyped particles. However, the addition of factor
H increased the luciferase activity by 50% in cells challenged
with H3N2 pseudotyped particles. VCP was found to reduce
luciferase reporter activity of H1N1 transduced MDCK cells by
45%. As is the case with factor H, VCP also enhanced the reporter
activity of MDCK cells transduced with H3N2 pseudotyped
lentiviral particles by 30%, suggesting the ability of factor H
and VCP to enhance viral infectivity through binding to cell
surface bound HA found on infected MDCK cells. Our results
are consistent with a previous study showing anti-viral activity
of Stachyflin, which was found to be resistant against H3N2 due
to differences in potential binding pockets for Stachyflin on HA
molecule (72).
In conclusion, data from restriction of M1 mRNA levels,
pro-inflammatory cytokine responses, and luciferase reporter
activity highlights the potential of factor H and VCP as cell
entry inhibitors against the H1N1 IAV subtype. It appears
that factor H and VCP restrict viral entry for H1N1, whilst
conversely promoting H3N2 entry, which may be due to the
inherent antigenic variations in binding sites for HA or NA.
Further studies are required to pinpoint the specific molecular
interactions of factor H and VCP against HA and NA by
investigating a range of IAV strains with antigenic variability.
This will not only provide further data on the pathogenesis of
IAV infection, but also the utility of factor H and VCP, and
their recombinant CCP modules, as possible cell entry inhibitors
against IAV.
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